INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

瑞戈非尼 医学 耐火材料(行星科学) 安慰剂 危险系数 临床终点 队列 癌症 内科学 无进展生存期 生活质量(医疗保健) 肿瘤科 胃肠病学 外科 置信区间 总体生存率 临床试验 结直肠癌 病理 护理部 替代医学 物理 天体生物学
作者
Nick Pavlakis,Kohei Shitara,Katrin Marie Sjoquist,Andrew Martin,Anthony Jaworski,Niall C. Tebbutt,Yung‐Jue Bang,Thierry Alcindor,Chris O’Callaghan,Andrew Strickland,Sun Young Rha,Keun‐Wook Lee,Jin-Soo Kim,Li‐Yuan Bai,Hiroki Hara,Do‐Youn Oh,Sonia Yip,John Zalcberg,Timothy Price,John Simes,David S. Goldstein
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
标识
DOI:10.1200/jco.24.00055
摘要

PURPOSE Treatment options for refractory advanced gastric and esophagogastric junction cancer (AGOC) are limited. Regorafenib, an oral multikinase inhibitor, prolonged progression-free survival (PFS) versus placebo in the INTEGRATE I phase II trial. INTEGRATE IIa was designed to examine whether regorafenib improved overall survival (OS). METHODS A double-blind placebo-controlled phase III trial compared regorafenib and best supportive care (BSC) versus placebo and BSC for participants with confirmed evaluable metastatic/advanced AGOC who failed ≥two prior therapies on a 2:1 random assignment, stratified by tumor location, geographic region (Asia v rest of world), and prior vascular endothelial growth factor inhibitors. The primary end point was OS. Treatment efficacy on OS was first tested in the pooled INTEGRATE I + INTEGRATE IIa cohort and, if significant, then in the INTEGRATE IIa cohort. Secondary end points were PFS, objective response rate, safety, and quality of life (QoL). RESULTS INTEGRATE IIa enrolled 251 participants: 157 from Asia and 94 from rest of world and 169 received regorafenib and 82 received placebo. No significant heterogeneity was observed between INTEGRATE I and INTEGRATE IIa studies on OS. Pooled OS analysis hazard ratio (HR) was 0.70 (95% CI, 0.56 to 0.87; P = .001; 361 events). INTEGRATE IIa alone OS HR was 0.68 (95% CI, 0.52 to 0.90; P = .006; 238 events), the median OS was 4.5 months versus 4.0 months, and 12-month survival rates were 19% and 6%, for regorafenib versus placebo, respectively. After a preplanned adjustment for multiplicity, there were no statistically significant differences across regions or other prespecified subgroups. Regorafenib improved PFS (HR, 0.53 [95% CI, 0.40 to 0.70]; P < .0001) and delayed deterioration in global QoL (HR, 0.68 [95% CI, 0.52 to 0.89]; P = .0043). The toxicity profile was consistent with that of previous reports. CONCLUSION Regorafenib improves survival compared with placebo in refractory AGOC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
IBMffff应助无限老三采纳,获得200
1秒前
Sheldon发布了新的文献求助10
3秒前
搜集达人应助民族风采纳,获得10
4秒前
4秒前
linger完成签到,获得积分10
5秒前
5秒前
6秒前
下辈子不读书做只猪完成签到 ,获得积分10
6秒前
所所应助四元采纳,获得10
6秒前
shijin135完成签到,获得积分10
7秒前
潇洒的如松完成签到,获得积分10
7秒前
Hannah完成签到,获得积分10
8秒前
8秒前
淡淡安筠发布了新的文献求助10
9秒前
cmq完成签到 ,获得积分10
9秒前
Cassiopiea19完成签到,获得积分10
9秒前
linger发布了新的文献求助10
9秒前
10秒前
在水一方应助Master采纳,获得10
10秒前
满意发布了新的文献求助10
11秒前
11秒前
千叶发布了新的文献求助10
11秒前
未语的阳光完成签到 ,获得积分10
12秒前
民族风发布了新的文献求助10
14秒前
16秒前
风华完成签到,获得积分10
17秒前
17秒前
zdl完成签到,获得积分10
19秒前
20秒前
四元发布了新的文献求助10
20秒前
Annie发布了新的文献求助10
22秒前
23秒前
个性莺完成签到,获得积分10
24秒前
yue完成签到 ,获得积分10
25秒前
25秒前
Master发布了新的文献求助10
25秒前
lyyydia发布了新的文献求助10
26秒前
liangx完成签到 ,获得积分10
26秒前
Ava应助小常不馋采纳,获得10
26秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3151736
求助须知:如何正确求助?哪些是违规求助? 2803153
关于积分的说明 7852024
捐赠科研通 2460525
什么是DOI,文献DOI怎么找? 1309844
科研通“疑难数据库(出版商)”最低求助积分说明 629061
版权声明 601760